reported positive results from a phase III trial of alpelisib in HR-positive, HER2-negative advanced breast cancer at the ESMO 2018 Congress .
Patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, two forms of non-Hodgkin lymphoma (NHL), who become resistant to or relapse after standard chemotherapy and antibody-based regimens have a poor prognosis.
Seeking a more effective treatment for NHLs, researchers developed a macrophage-activating monoclonal antibody dubbed Hu5F9-G4 (hereafter 5F9; Forty Seven). In a recently reported phase Ib trial, the drug induced a high rate of durable responses in patients with DLBCL and follicular lymphoma (N Engl J Med 2018; 379:1711-21) .
Forty Seven cofounders Ravi Majeti, MD, PhD, and Irv Weissman, MD, of Stanford University in California, and their colleagues previously established that some cancer cells express high levels of CD47, an antiphagocytic signal that allows them to evade macrophages (Cell 2009; 138:286-99) . "It drew our attention because CD47 is essentially a checkpoint inhibitor for the innate immune system, for macrophages," Majeti says.
The researchers developed 5F9 to block CD47 and its ligand, SIRPα-and thus provoke macrophages to recognize and attack cancer cells. In preclinical studies, they showed that the drug is active in various forms of lymphoma (Cell 2010; 142:699-713) . Moreover, they demonstrated that the drug augmented the activity of rituximab (Rituxan; Genentech), an anti-CD20 therapy commonly used to treat B-cell lymphomas.
For the clinical trial-the first to test 5F9 in combination with rituximabresearchers enrolled 22 patients: 15 with DLBCL and seven with follicular lymphoma. Patients had received a median of four prior therapies, and 95% had disease that was resistant to rituximab.
Overall, 11 patients responded to the drug, with eight complete responsesfive in DLBCL and three in follicular lymphoma. Additionally, at a median follow-up of 6.2 months in the DLBCL group and 8.1 months in follicular lymphoma group, 91% of patients continued to respond. The most common At the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, clinicians reported findings from the SOLAR-1 trial, which evaluated the PI3Kα inhibitor alpelisib (Novartis) in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer that had progressed on or after treatment with an aromatase inhibitor. Researchers showed that alpelisib nearly doubled median progression-free survival (PFS) compared with placebo-from 5.7 months to 11 months-when given with the antiestrogen fulvestrant to patients with PIK3CA-mutant disease.
Overall response rates were also greater in the alpelisib study arm: 36% versus 16%. Plus, toxicity levels proved manageable, with 5% of trial participants in the alpelisib arm discontinuing study treatment due to adverse events, compared with 1% in the control arm.
"We have a tolerable agent with a manageable side-effect profile that results in a pretty remarkable response rate and a clinically meaningful extension of progression-free survival," says Dejan Juric, MD, director of the Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center in Boston, who co-led the trial with Fabrice André, MD, PhD, of Institut Gustave Roussy in Villejuif, France.
Approximately 40% of patients with HR-positive breast tumors harbor driver mutations in PIK3CA, which encodes the alpha isoform of PI3K targeted by alpelisib. That's made PI3Kα inhibition an attractive strategy for these patients-although initial drugdiscovery efforts were less targeted.
Pan-PI3K inhibitors such as buparlisib (Novartis) and pictilisib (Roche) fared poorly, with problematic safety profiles or lack of efficacy scuttling their clinical advancement. Earlier this year, Roche halted development of its β-sparing PI3K blocker taselisib following disappointing results from the SANDPIPER trial. In that phase III study of women with PIK3CA-mutant disease, taselisib plus fulvestrant offered only a 2-month PFS advantage over placebo plus fulvestrant, and 17% of taselisib recipients discontinued treatment due to side effects.
Part of the difference between the success of alpelisib and taselisib may be attributed to clinical management, says Filip Janku, MD, PhD, of The University of Texas MD Anderson Cancer Center's Department of Investigational Cancer Therapeutics in Houston, who was not involved in either trial. In SOLAR-1, he says, researchers seem to have done "a far better job of proactively managing side effects," such as hyperglycemia and rash, with quick and early interventions that helped avoid the high rate of withdrawal from SANDPIPER.
Juric, however, thinks the lower discontinuation rate with alpelisiband thus higher efficacy with more patients staying on the drug-boils down to pharmacology. "The main reason is a much wider therapeutic index with alpelisib," he says. Taselisib, owing to its action against the gamma and delta isoforms of PI3K, can trigger gastrointestinal side effects such as colitis that can be difficult to manage. Alpelisib, because it hits only the alpha isoform, avoids these problems. It does, however, cause a high rate of hyperglycemia, which can be reversed with metformin.
The only PI3K-targeted agents currently approved-the PI3Kg inhibitor idelalisib (Zydelig; Gilead) and the pan-PI3K inhibitor copanlisib (Aliqopa; Bayer)-are reserved for hematologic malignancies. Alpelisib could join that list based on SOLAR-1 data, but the "holy grail," says Juric, would be "an inhibitor that preferentially hits just the mutant PI3Kα and not the wildtype enzyme." He and others are now clinically evaluating a next-generation inhibitor called GDC-0077 (Genentech) that, based on preclinical data, may do exactly that. www.aacrjournals.org he says. "I would hope that this will become something that's beneficial across many diseases and many malignancies." -Catherine Caruso n
ZW25 Effective in HER2-Positive Cancers
A novel anti-HER2 therapy, ZW25 (Azymetric), is effective and well tolerated in patients with a variety of HER2-positive cancers, according to results presented at the 2018 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland. In a phase I basket trial, patients treated with the drug-most of whom had gastroesophageal or colorectal cancer-had a high objective response rate with only mild side effects.
HER2 can be overexpressed in various cancers, including breast, gastroesophageal, colorectal, biliary, and salivary gland. However, although several HER2-targeted therapies have been FDA approved for HER2-positive breast cancer, trastuzumab (Herceptin; Genentech) is the only one approved for a HER2-positive cancer other than breast cancer: Its use is limited to first-line treatment of metastatic gastroesophageal cancer.
"There is an unmet need towards developing better treatment approaches for these other cancers that have a high expression of the HER2 receptor," says Murali Beeram, MD, of the START Center for Cancer Care in San Antonio, TX, who presented the findings.
ZW25 is a bispecific antibody that simultaneously binds to two HER2 epitopes: ECD4, the trastuzumab binding domain, and ECD2, the pertuzumab (Perjeta; Genentech) binding domain. Preclinical research suggested that ZW25 has strong antitumor activity at a range of HER2 expression levels and may more effectively silence HER2 signaling than trastuzumab or pertuzumab. It also stimulates the immune system. Now, researchers are testing the agent in a phase I basket trial of HER2-positive cancers.
Researchers enrolled 24 patients with HER2-positive cancers other than breast cancer, including 10 with gastroesophageal, five with colorectal, and nine with other malignancies. Patients had received a median of three prior therapies, and 71% had previously received trastuzumab. side effects were chills, headache, and anemia, and most were grade 1 or 2. "It's really encouraging to have a novel target that shows efficacy and is extremely well tolerated," says senior author Ranjana Advani, MD, also of Stanford. She acknowledges that the results need to be validated in a larger patient cohort, and a phase II trial of the drug duo is under way. Other trials are testing 5F9 alone and in combination with other therapies for various types of hematologic malignancies and solid tumors.
"It looks like a promising combination that warrants more study," says Brad Kahl, MD, of Washington University School of Medicine in St. Louis, MO, who was not involved in the study. "It's very nice to see a clinical experience that validates what was seen in the laboratory." He notes that because the combination has mild, manageable side effects, it may prove particularly beneficial in older patients with aggressive, relapsed lymphomas who cannot tolerate other treatments.
Stephen Ansell, MD, PhD, of Mayo Clinic in Rochester, MN, who was also not connected to the research, is impressed that the combination elicited responses in patients who were refractory to rituximab alone. He says that this may be because CD47 inhibition amplifies rituximab's ability to attract macrophages to cancer cells.
The study not only demonstrates the potential of 5F9 as a treatment for NHL, Ansell adds, but also may signal a broader shift in the field. "We've predominantly focused on T cells as the way in which the immune system is getting after the tumor. This now allows us to take cells like macrophages and get them to be part of the antitumor response as well,"
Overall, patients had a median progression-free survival of 6.2 months. Of 17 evaluable patients, seven (41%) had an objective response to the drug, and seven (41%) had stable disease, for a disease control rate of 82%. Diarrhea, infusion reactions, and nausea were the most common side effects, and most were classified as grade 1 or 2; no grade 4 or 5 side effects were observed.
"These are very exciting results, especially for the kind of tumors that we're talking about-if we can reproduce these results consistently in additional testing, it may mean an effective treatment for patients who, at this point, don't have a treatment option," Beeram says. He notes that the trial is still ongoing, with expansion cohorts being added for gastroesophageal cancers. Planning is also under way for phase II trials that will test the drug alone and in combination with chemotherapy.
ZW25 is also under study in HER2-positive breast cancers. Results from the same phase I trial presented at the 2018 American Society of Clinical Oncology Annual Meeting in Chicago, IL, indicated that six out of 13 patients with breast cancer (46%) responded to the drug.
To symposium co-chair Antoni Ribas, MD, PhD, of the University of California, Los Angeles, who is not involved in the research, ZW25 stands out due to its novel binding mechanism and strong early clinical data. "The fact that this HER2-targeted bispecific antibody has responses in a phase I trial, even in patients who have progressed on trastuzumab, is really remarkable," he says.
Ribas adds that "these are promising results that warrant further clinical testing in HER2-positive cancers, and in particular, gastroesophageal cancers." -Catherine Caruso n
Larotrectinib OK'd for Cancers with TRK Fusions
A first-in-class TRK inhibitor has received accelerated approval for patients of all ages who have solid tumors harboring fusions in NTRK1, NTRK2, or NTRK3.
The tissue-agnostic approval of larotrectinib (Vitrakvi; Loxo Oncology) marks only the second time the 
